Lakewood-Amedex Biotherapeutics has dosed the first patient in its Phase 2a clinical trial testing Nu-3, a topical antimicrobial gel, for mildly infected diabetic foot ulcers. This trial aims to evaluate the safety and effectiveness of three Nu-3 concentrations and guide future development. The study addresses the challenge of antimicrobial resistance and could expand treatment options for diabetic foot infections. Topline results are expected in early 2027, with plans for a Phase 2b trial to follow.
Lakewood-Amedex Biotherapeutics' Phase 2a clinical trial dosing news is provided here with Pluang's Health sector market data as of Sep 24, 2026 18:22 WIB: Among 100 priced Health-sector US stocks, 37 rose and 59 fell today. Notable movers include NUWE (Nuwellis Inc) at USD 0.82 with a 1-day change of -3.17% and a typical hold time on Pluang of 23 days, HRTX (Heron Therapeutics Inc) at USD 0.30 up 3.06%, and BNGO (BioNano Genomics Inc) at USD 1.74 up 2.35%. The most notable figure is the 59 stocks that fell.
Lake Victoria Gold Ltd. reported that pretreatment involving attrition scrubbing and desliming significantly increased 24-hour gold extraction from 49.99% to 84.54% at its Imwelo Gold Project in Tanzania. This process also improved slurry handling an...
HawkEye 360 secured multiple contracts worth about $18 million in the Middle East, expanding its role in providing space-based signals intelligence and analytics. These contracts support regional defense and national security missions by delivering t...
Clarivate Plc announced the expiration and final results of its cash tender offer to repurchase up to $75 million of its 3.875% Senior Secured Notes due 2028. The offer expired on September 23, 2026, with $665.2 million of notes tendered, but only $7...
Stellar's XLM token price fell about 7% following BVNK's announcement that it has integrated Stellar as a payment rail for stablecoin transactions in over 130 countries. BVNK, now owned by Mastercard, uses Stellar's network for fast, low-cost busines...
Voyager Technologies announced a $350 million offering of convertible notes, causing its shares to fall more than 16%. The notes include capped calls to reduce dilution, which is estimated between 12-15%, though the share price decline exceeds this. ...
